**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934**

**(Amendment No. 2)\***

**EIGER BIOPHARMACEUTICALS, INC.**



(Name of Issuer)

**Common Stock**



(Title of Class of Securities)

**28249U105**



(CUSIP Number)

**December 31, 2018**



(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

* Rule 13d-1(b)
* Rule 13d-1(c)

xRule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



|  |  |
| --- | --- |
| CUSIP No. 28249U105 | **13G** |
|  |  |

1. Names of Reporting Persons

HBM Healthcare Investments (Cayman) Ltd.

1. Check the Appropriate Box if a Member of a Group (See Instructions)
	1. o
	2. o
2. SEC Use Only
3. Citizenship or Place of Organization Cayman Islands, British West Indies



|  |  |  |
| --- | --- | --- |
|  | 5. |  |
| Number of | 6. |  |
| Shares |  |
|  |  |
| Beneficially |  |  |
| Owned by |  |  |
| Each | 7. |  |
| Reporting |  |
|  |  |
| Person With: |  |  |
|  | 8. |  |

Sole Voting Power

0



Shared Voting Power

0



Sole Dispositive Power

0



Shared Dispositive Power

0



1. Aggregate Amount Beneficially Owned by Each Reporting Person 0
2. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) o
3. Percent of Class Represented by Amount in Row 9 0
4. Type of Reporting Person (See Instructions)

CO



2



|  |  |  |
| --- | --- | --- |
| **Item 1(a).** | Name of Issuer: |  |
|  | Eiger BioPharmaceuticals, Inc.. |  |
| **Item 1(b).** |  |  |
| Address of Issuer’s Principal Executive Offices: |  |
|  | 350 Cambridge Drive |  |
|  | Suite 350 |  |
|  | Palo Alto, CA 94306 |  |
|  |  |  |

**Item 2(a).**

**Item 2(b).**

**Item 2(c).**

**Item 2(d).**

**Item 2(e).**

**Item 3.**

Name of Person Filing:

HBM Healthcare Investments (Cayman) Ltd.



Address of Principal Business Office or, if none, Residence:

Governors Square

Suite #4-212-2

23 Lime Tree Bay Avenue

West Bay

Grand Cayman, Cayman Islands



Citizenship:

Cayman Islands, British West Indies



Title of Class of Securities:

Common Stock



CUSIP Number:

28249U105



**If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:**

Not applicable

3



**Item 4.** **Ownership**

1. Amount beneficially owned: 0
2. Percent of class: 0%
3. Number of shares as to which the person has:



1. Sole power to vote or to direct the vote: 0



1. Shared power to vote or to direct the vote: 0



1. Sole power to dispose or to direct the disposition of: 0
2. Shared power to dispose or to direct the disposition of: 0



**Item 5.** **Ownership of 5 Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x.

**Item 6.** **Ownership of More than 5 Percent on Behalf of Another Person**

Not applicable

**Item 7.** **Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.**

Not applicable

**Item 8.** **Identification and Classification of Members of the Group**

Not applicable

**Item 9.** **Notice of Dissolution of a Group**

Not applicable

4



**Item 10.** **Certification**

Not applicable

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and

correct.

|  |  |  |
| --- | --- | --- |
|  | February 14, 2019 |  |
|  | **HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD.** |  |
|  | By: /s/ Jean-Marc LeSieur |  |
|  |  | Jean-Marc LeSieur, Managing Director |  |
| **Attention:** | **Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)** |  |
|  | 5 |  |  |
|  |  |  |  |

